The company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association… read more.
Bristol Myers Squibb announced that the FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) from Sun Pharma UK Ltd. to treat severe alopecia areata in adults. Approval was based on… read more.
The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending the granting of a marketing authorisation for Poherdy in combination with trastuzumab and… read more.
Vertex Pharmaceuticals Incorporated announced data from a Phase IV study of Journavx (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults,… read more.
GE HealthCare announced that View has received 510(k) clearance from the FDA. Designed as a fast, diagnostic, zero‑footprint viewer, View serves as the core anchor of the Genesis… read more.
Ardelyx Inc. announced the publication of data from its IBS-C clinical development program, “Tenapanor is associated with earlier and sustained symptom relief in IBS-C: a post hoc analysis”… read more.
Tenpoint Therapeutics, Ltd., announced that the FDA approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, previously known as Brimochol PF, the first and only dual-agent eye drop… read more.
Pfizer Inc. announced the FDA has granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux ) and fluorouracil-based chemotherapy for the treatment of adult patients with… read more.
The EMA has recommended the refusal of the marketing authorisation for Daybue, intended for the treatment of Rett syndrome, a rare inherited condition that affects the brain and… read more.
The EMA has recommended the refusal of the marketing authorisation for Iloperidone Vanda Pharmaceuticals, a medicine intended for the treatment of schizophrenia and manic or mixed episodes associated… read more.
BD (Becton, Dickinson and Company) announced it has obtained CE Marking for the Revello Vascular Covered Stent, a next-generation endovascular solution for the treatment of atherosclerotic lesions in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
